Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3–18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study)

Authors:

Abstract
No abstract available
Funding Information
  • National Center for Genetic Engineering and Biotechnology

This publication has 21 references indexed in Scilit: